NCT00594737

Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia

An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Tiffany Chow, MD · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Memantine has been approved for use in Alzheimer's disease. Its mechanism of action raises questions of whether it can also be effective for non-Alzheimer's dementias such as frontotemporal dementia (FTD), which currently has no disease-modifying treatment. This is an open-label study to probe the effects of memantine in 15 outpatients diagnosed with FTD, as shown objectively by comparing PET scans performed before and after use of the medication. The specific type of PET scan, FDG-PET, allows the investigators to gauge the effects of memantine on cortical activity levels. The investigators hypothesize that subjects on memantine will show normalization of cortical metabolic activity.

Conditions

• Frontotemporal Dementia

Interventions

Type	Name	Description
DRUG	memantine hydrochloride	memantine hydrochloride oral tablets, 10mg po bid

Timeline

• Start date: 2007-10-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2008-01-16
• Last updated: 2012-06-04

Locations

1 site across 1 country: Canada